Clinical Trials Browser

Phase 1/2 × Withdrawn × ruxolitinib × Clear all

NCT04354727 2022-07-12

A Study of APG-1252 in Patients With Myelofibrosis Who Progressed After Initial Therapy

Phase 1/2 Withdrawn

Polycythemia Vera, Thrombocytosis, Primary Myelofibrosis

NCT02973711 2021-02-16

A Study of Ruxolitinib in Combination With Nilotinib in Patients With Chronic Phase CML

Phase 1/2 Withdrawn

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive